Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma
Dateline City:
THOUSAND OAKS, Calif. and KENILWORTH, N.J.
Collaboration Includes Additional Select Advanced Solid Tumors
THOUSAND OAKS, Calif. and KENILWORTH, N.J. – Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen’s CD19 bispecific T cell engager (BiTE®), and KEYTRUDA is Merck’s anti-PD-1 antibody.
Language:
English
read more
Source: Merck - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Lymphoma | Merck | Non-Hodgkin's Lymphoma | Pharmaceuticals | Study